Validation of the Genetic Signature 354849 as a Prognostic Method

RecruitingOBSERVATIONAL
Enrollment

189

Participants

Timeline

Start Date

September 30, 2019

Primary Completion Date

May 30, 2024

Study Completion Date

May 30, 2024

Conditions
Cervix Cancer
Interventions
OTHER

Genetic signature

The RNA will be extracted from the tumor sample with a special kit and a q-PCR will be performed. In order to quantify the genetic expression, the comparative method called Cycle threshold or Crossing point will be used.

Trial Locations (2)

14080

RECRUITING

Instituto Nacional de Cancerologia, Mexico City

RECRUITING

David Cantu de Leon, Mexico City

All Listed Sponsors
lead

National Institute of Cancerología

OTHER_GOV

NCT04067882 - Validation of the Genetic Signature 354849 as a Prognostic Method | Biotech Hunter | Biotech Hunter